medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2018, Number 4

<< Back Next >>

Neumol Cir Torax 2018; 77 (4)

Drug resistance patterns in migrant population with pulmonary tuberculosis

Orozco-Andrade I, Acosta-Loya JA, Bravo-Rodríguez G, Martínez-Lozano FN, Espinoza-Hernández ME, Enríquez-Porras A, Durán-Peña OA, Orozco-Béjar IA

Language: Spanish
References: 20
Page: 247-257
PDF size: 193.38 Kb.


ABSTRACT

Objective: To describe the drug resistance pattern of pulmonary tuberculosis in migrant population. Material and methods: The databases of pulmonary tuberculosis (PTB) cases confirmed with culture positive were reviewed. Results: According to the medical and radiographic evaluation of 394,482 applicants that were going to emigrate to the United States, 8,775 (2.2%) were patient with suspected TB, of which, 157 (1.8%) were positive for PTB. Twenty-four patients did not have evidence of drug sensitivity, and three more had negative cultures, therefore, the investigation was carried out with only 130 cases. Only three were multidrug-resistant, 18 mono-resistant and five poly-resistant. 52% were men. The age groups with the highest number of cases were those from 51 to 60 and 71 to 80 years. Conclusions: The resistance to anti-tuberculosis drugs is an obstacle to effectively treat TB. Case management becomes difficult and the challenge is compounded by catastrophic economic and social costs. Hence the need to work on the prevention of the factors conditioning drug resistance; and on the other hand, to insist that the pharmaceutical industry must create a new and effective anti-tuberculosis drugs with fewer side effects and at a lower cost.


REFERENCES

  1. Orozco AI. Tuberculosis. United States. CreateSpace; 2017.

  2. WHO: Global Tuberculosis Report 2017. France.

  3. Túñez-Bastida B, García-Ramos MR, Pérez del Molino ML, Lado-Lado FL. Epidemiología de la tuberculosis. Med Integral 2002;39(5):172-180.

  4. Secretaría de Salud. Guía para la atención de pacientes con tuberculosis resistente a fármacos. México; 2010.

  5. WHO: Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis 2014.

  6. Francis J. Curry National Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd ed.

  7. Caminero JA. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013. International Union Against Tuberculosis and Lung Disease (The Union).

  8. Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis 2013;57(8):1081-1093. doi: 10.1093/cid/cit452.

  9. Sinha P, Srivastava GN, Gupta A, Anupurba S. Association of risk factors and drug resistance pattern in tuberculosis patients in North India. J Glob Infect Dis 2017;9(4):139-145. doi: 10.4103/jgid.jgid_167_16.

  10. Smith SE, Pratt R, Trieu L, et al. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014. Clin Infect Dis 2017;65(9):1437-1443. doi: 10.1093/cid/cix561.

  11. Orejel I, Castellanos M, Marín D, Mendoza A, Harries AD. Culture and drug sensitivity testing among patients with pulmonary tuberculosis in Mexico: national data for 2009-2013. Rev Panam Salud Publica 2016;39(1):65-68.

  12. Ferrer G, Acuna-Villaorduna C, Escobedo M, Vlasich E, Rivera M. Outcomes of Multidrug-resistant tuberculosis among binational cases in El Paso, Texas. Am J Trop Med Hyg 2010;83(5):1056-1058. doi: 10.4269/ajtmh.2010.10-0145.

  13. Becerril-Montes P, Said-Fernández S, Luna-Herrera J, et al. A population-based study of first and second-line drug-resistant tuberculosis in a high-burden area of the Mexico/United States border. Mem Inst Oswaldo Cruz 2013;108(2):160-166.

  14. Granich RM, Balandrano S, Santaella AJ, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997. Arch Intern Med 2000;160(5):639-644.

  15. Velasco RVM, Padua GA, Esquivel MC, Sánchez CO, Martínez OV, Cicero SR. Epidemiología y resistencia primaria a fármacos en casos incidentes de tuberculosis pulmonar. Rev Med IMSS 2004;42(4):303-308.

  16. Bojorquez I, Barnes RF, Flood J, et al. Multidrug-resistant tuberculosis among patients in Baja California, Mexico, and Hispanic patients in California. Am J Public Health 2013;103(7):1301-1305. doi: 10.2105/AJPH.2012.301039.

  17. Fisher-Hoch SP, Whitney E, McCormick JB, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008;40(11-12):888-893. doi: 10.1080/00365540802342372.

  18. Bojorquez-Chapela I, Bäcker CE, Orejel I, et al. Drug resistance in Mexico: results from the National Survey on Drug-Resistant Tuberculosis. Int J Tuberc Lung Dis 2013;17(4):514-519. doi: 10.5588/ijtld.12.0167.

  19. Zazueta-Beltran J, Muro-Amador S, Flores-Gaxiola A, Llausas-Magaña E, León-Sicairos N, Canizalez-Roman A. High rates of multidrug-resistant Mycobacterium tuberculosis in Sinaloa State, Mexico. J Infect 2007;54(4):411-412.

  20. Zazueta-Beltran J, León-Sicairos C, Canizalez-Roman A. Drug resistant Mycobacterium tuberculosis in Mexico. J Infect Dev Ctries 2009;3(3):162-168.




2020     |     www.medigraphic.com